This article has been updated to include a statement from Exact Sciences.

NEW YORK (GenomeWeb) – Exact Sciences' shares fell as much as 7 percent on Monday after short-seller Citron Research released a report calling the company's Cologuard colon cancer test "inferior" and claimed it had proof that the company's stock "will soon be cut in half."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.